Results 91 to 100 of about 128,993 (222)

Denosumab discontinuation and fracture risk: getting the balance right

open access: yesInternal Medicine Journal, EarlyView.
Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley   +1 more source

Dealing with Rising Health Care Costs: The Case of Pharmaceuticals [PDF]

open access: yes
Pharmaceuticals; Advertising; Generic Market Entry; Reference Pricing; Parallel ...
Königbauer, Ingrid
core  

Acknowledgement to Reviewers of Pharmaceuticals in 2013

open access: yes, 2014
The editors of Pharmaceuticals would like to express their sincere gratitude to the following reviewers for assessing manuscripts in ...
Pharmaceuticals Editorial Office
core   +1 more source

Acknowledgment to Reviewers of Pharmaceuticals in 2020

open access: yes, 2021
Peer review is the driving force of journal development, and reviewers are gatekeepers who ensure that Pharmaceuticals maintains its standards for the high quality of its published papers [...
Pharmaceuticals Editorial Office Pharmaceuticals Editorial Office   +2 more
core   +1 more source

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

open access: yesActa Ophthalmologica, Volume 104, Issue 8, Page 926-939, December 2026.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car   +3 more
wiley   +1 more source

Acknowledgement to Reviewers of Pharmaceuticals in 2015

open access: yes, 2016
The editors of Pharmaceuticals would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2015.
Pharmaceuticals Editorial Office
core   +1 more source

Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis

open access: yesArthritis Research & Therapy
Background We compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis (RA) initiating etanercept biosimilar (ETA-B) or originator (ETA-O).
Marina G. Birck   +12 more
doaj   +1 more source

Acknowledgement to Reviewers of Pharmaceuticals in 2016

open access: yes, 2017
The editors of Pharmaceuticals would like to express their sincere gratitude to the following reviewers for assessing manuscripts in ...
Pharmaceuticals Editorial Office
core   +1 more source

Anti-resorptive therapy with denosumab in elderly and senile patients with osteoporosis: a narrative review and clinical recommendations

open access: yesConsilium Medicum
Senile osteoporosis represents one of the most pressing challenges in modern geriatric medicine, characterized by high prevalence, delayed diagnosis, and severe complications such as low-energy fractures, which are associated with disability, loss of ...
Ekaterina N. Dudinskaya   +2 more
doaj   +1 more source

Capacity building in medicines development and regulation in Africa—Overview on recent progress

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3759-3769, November 2026.
Aims Despite advances in health research and digital innovation, many African countries continue to face substantial resource constraints, fragmented capacity‐building efforts and a shortage of skilled professionals in medicines development and regulatory science.
Tirhani Maluleke   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy